Back to today’s briefing

Story perspectives

FDA Approves SPRAVATO: New Hope for Depression Sufferers

1/21/2025

38 5

Summary

Story summary

In a groundbreaking move, the FDA has greenlit Johnson & Johnson's SPRAVATO (esketamine) nasal spray as the first independent treatment for adults battling treatment-resistant depression. This innovative therapy promises rapid relief, often within just 24 hours, offering hope to those who have struggled with traditional antidepressants. SPRAVATO is now accessible at certified treatment centers nationwide.

1 of 1

Story summary

In a groundbreaking move, the FDA has greenlit Johnson & Johnson's SPRAVATO (esketamine) nasal spray as the first independent treatment for adults battling treatment-resistant depression. This innovative therapy promises rapid relief, often within just 24 hours, offering hope to those who have struggled with traditional antidepressants. SPRAVATO is now accessible at certified treatment centers nationwide.